Get the Stockscreener App
350.78
2.56%
8.99
After Hours:
351.25
0.47
+0.13%
Natera Inc stock is traded at $350.78, with a volume of 1.77M.
It is up +2.56% in the last 24 hours and up +13.10% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$341.79
Open:
$340.34
24h Volume:
1.77M
Relative Volume:
1.31
Market Cap:
$50.56B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-213.73
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
+8.14%
1M Performance:
+13.10%
6M Performance:
+86.61%
1Y Performance:
+103.61%
1-Day Range:
$338.82
$351.78
1-Week Range:
$320.65
$351.78
52-Week Range:
$157.43
$351.78
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
350.78 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
641.44 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
209.33 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
IQV
Iqvia Holdings Inc
|
269.65 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.26 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Understanding Momentum Shifts in (NTRA) - Stock Traders Daily
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - webull.com
Natera(NTRA.US) Officer Sells US$16.4 Million in Common Stock - Moomoo
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com South Africa
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - Investing.com
Executive chair of Natera (NTRA) sells 50,000 shares - Stock Titan
Insider at Natera (NTRA) plans stock sale, with size detailed in new SEC notice - Stock Titan
NTRA Maintains Buy Rating by UBS -- Price Target Raised to $435 - GuruFocus
3 Reasons Investors Love Natera (NTRA) - Yahoo Finance
UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating - Moomoo
Jim Cramer Calls Natera (NTRA) “a Promising Story” - Yahoo Finance
Net current asset value per share of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
Fed. Circ. Urged To Overturn Natera's Cancer Test Patent Win - Law360
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia) - The Motley Fool
NTRA Initiated Coverage by Rothschild & Co -- Price Target Set a - GuruFocus
Can Natera (NTRA) Justify Its Valuation As Signatera Lymphoma Data Lifts Sentiment? - simplywall.st
Rothschild Redburn initiates Natera stock with buy on MRD leadership By Investing.com - Investing.com Nigeria
Rothschild Redburn initiates Natera stock with buy on MRD leadership - Investing.com
Debt to assets ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Net debt of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - tradingview.com
Natera, Inc. (NTRA) Stock Analysis: A $47.31 Billion Healthcare Innovator with Strong Buy Ratings - DirectorsTalk Interviews
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Price to earnings forward of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - tradingview.com
Diluted earnings per share (diluted EPS) of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - TradingView
Gross profit of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
Natera Inc Cert Deposito Arg Repr 0.019607 Sh Revenue Breakdown – BCBA:NTRA.CI - TradingView
Natera Inc Cert Deposito Arg Repr 0.019607 Sh Revenue Breakdown – BCBA:NTRA - TradingView
Guggenheim maintains Buy on Natera, raises target to $290 - scanx.trade
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAC - TradingView
The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership - simplywall.st
Natera CEO Steven Chapman sells $545k in NTRA shares By Investing.com - Investing.com South Africa
Natera president Solomon Moshkevich sells over $5.9m in shares By Investing.com - Investing.com South Africa
Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga
Natera stock trades near 52-week high as guidance and regulatory wins support growth - ad-hoc-news.de
Natera Inc (NTRA) CEO and President Steven Chapman Sells 1,698 S - GuruFocus
Natera president Solomon Moshkevich sells over $5.9m in shares - investing.com
Natera CEO Steven Chapman sells $545k in NTRA shares - Investing.com
Natera (NASDAQ: NTRA) exec sells shares for taxes and under pre-set plan - Stock Titan
Natera Unlocks Broader Signatera Adoption With FDA, PMDA And NCCN Milestones! - Smartkarma
Natera: $8.25M Prenatal Test Class Action Settlement Approved - Wansom AI
I would put Natera on my watch list and not chase the stock here, says Jim Cramer - CNBC
After recent stock sales, Natera (NASDAQ: NTRA) exec files notice to sell more shares - Stock Titan
Planned stock sale by Natera (NTRA) holder follows 41,124-share trade - Stock Titan
Natera (NASDAQ: NTRA) executive plans nearly $1M share sale after $2M in recent trades - Stock Titan
NTRA Looks 47.2% Overvalued on GF Value™ - GuruFocus
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma - Stock Titan
Natera teams with Angiex on cancer drug trial monitoring - Fierce Biotech
Pretax income of Natera, Inc. – LSX:A14VPJ - TradingView
Natera, Inc. (NTRA) Stock Analysis: A Healthcare Powerhouse with a 3.21% Upside Potential - DirectorsTalk Interviews
Natera Stock (NTRA) Opinions on Recent Price Surge - moomoo.com
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? - The Motley Fool
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):